Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Trans people have often been denied treatment in Pakistan because doctors could not decide whether to treat them in a male or female ward, and have even died for lack of care. The government plans to set up separate wards in hospitals around the country for transgender patients, according to Dr. Zafar Mirza, a special aide to Prime Minister Imran Khan for health services. Pakistan — a conservative, majority Muslim nation — officially recognized transgender as a third gender in 2012. Yet transgender people are still largely confined to the margins of society, often taunted in public, ostracized by family and targeted in violent attacks. Most transgender people in Pakistan are forced to survive by begging, dancing or prostitution. Sex reassignment surgery requires a court order, family approval, a psychiatrist’s note and a medical recommendation. The Supreme Court ordered the government to list transgender as a third gender on ID cards, and the national agency responsible for issuing them will also handle the new health cards. The health ministry will immediately start giving health cards to all transgender people who are registered, said Dr. Mirza. He said anyone who wants to change the listing on their ID to transgender will have a “one-time option” to do so. He didn’t specify how long that period would last. Speaking to reporters in the capital of Islamabad, he stressed that the government is legally responsible for ensuring all citizens’ rights, including access to healthcare nationwide. Transgender people face greater peril in more conservative areas of Pakistan, where Islamic extremists associate them with homosexuality and prostitution. But there are also signs of progress. In 2018, Marvia Malik made history by becoming Pakistan’s first transgender newscaster at just 21 years old. ____ Khan reported from Karachi, Pakistan

Output: Pakistan issues health IDs for trans people to improve care.


Input: Consider Input: The story makes clear the “big unknown” remains the price and “how much people are willing to spend to cut a day or so off of a bout of flu.” The story reports that Genentech, the drug’s manufacturer, said it’s too early to comment on the drug’s U.S. price. The story also notes that in Japan, where the drug was invented, it “sells for the equivalent of about $43.50.” The story uses terms like “a little more than a day” and “nearly a day” and “substantially” to describe the drug’s reduction in flu symptoms, fever, and coughing and sneezing, respectively. It does not explain, as the news release does, that: “Similar efficacy results were seen between baloxavir marboxil and [Tamiflu] in relation to duration of symptoms and fever reduction.” In other words, on the symptom front, both drugs were the same. According to the news release, a difference was seen in the length of time the virus was shed from the body (presumably through coughing and sneezing): 24 hours for baloxavir marboxil verses 72 hours for Tamiflu. The news release also states that there was also a difference seen in the level of virus in the nose and throat, but it provides no precise numbers. It is not known whether this benefit translates into less infection transmission, and the story should have made that clear. The news release issued by Genentech about the FDA’s decision to grant priority review describes baloxavir marboxil’s most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu. The STAT News story does not mention any potential harms. This evidence comes from the randomized phase III Capstone-1 study the FDA will review, which included 1,436 people in the US and Japan. It excluded people older than 64. The news story does not note this exclusion, nor does it state a key problem with this study: It has never been published in a peer-reviewed journal (instead, a study abstract was released as part of ID Week 2017). This means the full data analysis has never been seen by anyone other than the researchers. We explained why this is important in February 2018, when we discussed news coverage of the drug’s approval in Japan. The 2017-2018 flu season was the worst the US had experienced in nearly a decade. The flu impacted the entire country, and was responsible for 172 pediatric deaths. The news article did not use these or any other flu-related statistics to increase fear about the flu and, in turn, the need for this medication. The article includes two sources: Mark Eisner, Genentech’s VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization’s influenza collaborating center at St. Jude Children’s Research Hospital in Memphis. Eisner’s affiliation with Genentech, the drug’s manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on what–if anything–is known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths. The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and that baloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days. It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication. The story explains that it’s been more than 20 years since a new class of flu drug has been developed and marketed. (It is available in Japan.) The catalyst for the story was a news release issued by Genentech about the FDA granting priority review of baloxavir marboxil, but the story does not use direct quotes from the news release.

Output: A flu drug — shown to reduce the duration of symptoms — could upend treatment in U.S.


Input: Consider Input: The state Air Quality Control Commission, which passed the rule on an 8-1 vote, said the requirement applies to auto manufacturers, not buyers. It’s intended to boost the number of electric vehicles in a state struggling to control ozone pollution in its most heavily populated area. The minimum rises to 6.23% in 2025. Colorado is the 11th state to adopt zero-emission standards, according to Green Car Reports, which tracks developments in low-pollution vehicles. Two auto industry groups, Global Automakers and the Alliance of Automobile Manufacturers, applauded the rule. They said they had been working with Colorado officials on how to structure the requirement. John Bozzella, president of Global Automakers, said Colorado had adopted an innovative policy by collaborating with manufacturers. Environmental groups also welcomed the standards, but the Colorado Freedom to Drive Coalition called them costly and ineffective. “We believe commissioners did a disservice to all Coloradans, but especially Coloradans of modest means,” coalition spokeswoman Sara Almerri said. Regulators said the zero-emission standard is aimed at reducing ozone and greenhouse gases, which contribute to climate change. Democratic Gov. Jared Polis directed the Air Quality Control Commission to set a zero-emissions standard shortly after he took office in January. In a statement Friday, he said the new rule was “only the beginning” of the state’s work to reduce air pollution. Excessive ground-level ozone has plagued Colorado’s urban areas for years. Ozone is the main component of smog and can aggravate asthma and contribute to early deaths from respiratory disease. It’s created from pollution emitted by vehicles, the oil and gas industry and other sources. Ozone alerts have frequently flashed on signs over Denver freeways this summer, asking drivers to reduce car trips. Last week, the U.S. Environmental Protection Agency said Denver and the northern Colorado urban corridor failed to meet federal ozone standards and said the state must come up with a new plan to clean up the air. The state is also rewriting air pollution rules for the oil and gas industry. ___ This story has been corrected to say Colorado would be the 11th state to adopt zero-emissions requirements, not the 15th. ___ Follow Dan Elliott at http://twitter.com/DanElliottAP


Output: Colorado OKs electric car requirement to fight air pollution.